Exactly. I wouldn't underestimate Victoza in taking a big chunk of the GLP-1 market and certainly wouldn't think of it as a monopoly for bydureon. Will patients prefer the once-weekly formulation over a better pen delivery is yet to be seen.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.